Atenolol Market Size

  • Report ID: 4076
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Atenolol Market size was over USD 12.23 billion in 2024 and is anticipated to cross USD 24.53 billion by 2037, witnessing more than 5.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of atenolol is assessed at USD 13.33 billion.

The growth of the market can be attributed to the worldwide expanding ratio of hypertension among people, coupled with the surging awareness regarding the concerned complexities of hypertension.  As per the World Health Organization (WHO) data, an estimated 1.28 billion persons aged 30-79 years have hypertension across the globe, with the majority two-thirds residing in low- and middle-income nations. Further, the dynamically growing demand for antihypertensive drugs throughout the world is also projected to skyrocket the growth of the global atenolol market over the forecast period.

In addition to these, factors that are believed to fuel the market growth of atenolol include the significant rise in the aged population throughout the world, as aged people are more prone to have disorders comprising hypertension, cardiac diseases, diabetes, and so on. As stated by the World Health Organization, the global population of persons aged 60 and above is projected to surge from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the global population of people aged 60 and above is expected to augment to 2.1 billion by 2050. Further, poor lifestyle along with poor dietary habits among people is also estimated to fuel the market growth in the coming years.


Atenolol Market overview

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of atenolol is assessed at USD 13.33 billion.

The atenolol market size was over USD 12.23 billion in 2024 and is anticipated to cross USD 24.53 billion by 2037, witnessing more than 5.5% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of angina experiences, expansion in sedentary lifestyle, and increasing prevalence of arrhythmia will boost the market growth.

North America industry is set to hold largest revenue share of 40% by 2037, attributed to increasing prevalence of cardiac diseases, along with rising frequency of hypertension in the region.

The major players in the market are Intas Pharmaceuticals Limited, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Zydus Pharmaceuticals (USA) Inc., Ipca Laboratories Limited, Unichem Laboratories Limited, AstraZeneca PLC
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos